MA33751B1 - Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 - Google Patents

Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Info

Publication number
MA33751B1
MA33751B1 MA34869A MA34869A MA33751B1 MA 33751 B1 MA33751 B1 MA 33751B1 MA 34869 A MA34869 A MA 34869A MA 34869 A MA34869 A MA 34869A MA 33751 B1 MA33751 B1 MA 33751B1
Authority
MA
Morocco
Prior art keywords
orl
compounds
treatment
spirobridine
receptor antagonists
Prior art date
Application number
MA34869A
Other languages
Arabic (ar)
English (en)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Alma Maria Jimenez-Aguado
Blanco Celia Lafuente
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Escribano Miguel Angel Toledo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33751B1 publication Critical patent/MA33751B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un antagoniste de récepteur orl-1 de formule i, ses utilisations et procédés de préparation. Des antagonistes de orl-1 sont jugés utiles dans le traitement de la dépression et/ou le traitement du surpoids, de l'obésité, et/ou le maintien du poids après un traitement du surpoids ou de l'obésité. Certains composés ont également montré dans des modèles animaux que les composés de la présente invention sont utiles pour le traitement de migraines.
MA34869A 2009-11-16 2012-05-14 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 MA33751B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27
PCT/US2010/056180 WO2011060035A1 (fr) 2009-11-16 2010-11-10 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Publications (1)

Publication Number Publication Date
MA33751B1 true MA33751B1 (fr) 2012-11-01

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34869A MA33751B1 (fr) 2009-11-16 2012-05-14 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (fr)
EP (1) EP2501703B1 (fr)
JP (1) JP5680101B2 (fr)
KR (1) KR101363830B1 (fr)
CN (1) CN102612520B (fr)
AR (1) AR078863A1 (fr)
AU (1) AU2010319581C1 (fr)
CA (1) CA2796161C (fr)
CO (1) CO6541545A2 (fr)
CR (1) CR20130087A (fr)
DK (1) DK2501703T3 (fr)
DO (1) DOP2012000135A (fr)
EA (1) EA020848B1 (fr)
EC (1) ECSP12011902A (fr)
ES (1) ES2435814T3 (fr)
HK (1) HK1169988A1 (fr)
HN (1) HN2012001011A (fr)
HR (1) HRP20130967T1 (fr)
IL (1) IL219370A (fr)
JO (1) JO2887B1 (fr)
MA (1) MA33751B1 (fr)
ME (1) ME01537B (fr)
MX (1) MX2012005691A (fr)
MY (1) MY160665A (fr)
NZ (1) NZ600006A (fr)
PE (1) PE20121430A1 (fr)
PL (1) PL2501703T3 (fr)
PT (1) PT2501703E (fr)
RS (1) RS53018B (fr)
SI (1) SI2501703T1 (fr)
TW (1) TWI465453B (fr)
UA (1) UA107943C2 (fr)
WO (1) WO2011060035A1 (fr)
ZA (1) ZA201202967B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101637247B1 (ko) 2009-12-04 2016-07-07 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
WO2012052540A1 (fr) * 2010-10-21 2012-04-26 Universitaet Des Saarlandes Inhibiteurs sélectifs de cyp11b1 pour le traitement de maladies dépendantes du cortisol
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
PT2903440T (pt) 2012-10-02 2017-12-18 Bayer Cropscience Ag Compostos heterocíclicos como pesticidas
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
AR105821A1 (es) * 2015-09-09 2017-11-15 Lilly Co Eli COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
BR112019001439A8 (pt) 2016-07-29 2019-11-12 Pgi Drug Discovery Llc compostos e composições e usos dos mesmos
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sunovion Pharmaceuticials Inc. Methods of treating schizophrenia
JP6766273B2 (ja) 2017-03-02 2020-10-07 イーライ リリー アンド カンパニー Ｒｏｒ−ガンマ−ｔを阻害するのに有用な化合物
US10603320B2 (en) * 2017-03-02 2020-03-31 Eli Lilly And Company Compounds useful for inhibiting ROR-gamma-t
WO2019028165A1 (fr) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. Composés d'isochromane et leurs utilisations
JP7453148B2 (ja) 2018-02-16 2024-03-19 サノビオン ファーマシューティカルズ インク 塩、結晶形態、およびその製造方法
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
EP4135690A1 (fr) 2020-04-14 2023-02-22 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7 h-thiéno[2,3-c]pyran-7-yl)-n-méthylméthanamine pour le traitement de troubles neurologiques et psychiatriques
PE20231106A1 (es) 2020-08-26 2023-07-19 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos
WO2023154344A1 (fr) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Dérivés de 2-méthyl-4',5'-dihydrospiro[pipéridine-4,7'-thiéno[2,3-c]pyran] utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
CZ20032849A3 (en) * 2001-04-18 2004-03-17 Euro-Celtique S.A. Spiropyrazole compounds
WO2002088089A1 (fr) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
JP4356453B2 (ja) * 2001-07-23 2009-11-04 萬有製薬株式会社 ４−オキソイミダゾリジン−２−スピロピペリジン誘導体
MXPA04007242A (es) * 2002-01-28 2004-10-29 Pfizer Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1.
JPWO2003095427A1 (ja) 2002-05-10 2005-09-15 大正製薬株式会社 スピロ環化合物
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
WO2004022558A2 (fr) * 2002-09-09 2004-03-18 Janssen Pharmaceutica, N.V. Derives de 1,3,8-triazaspiro[4.5]decan-4-one a substitution hydroxyalkyle utiles pour traiter des maladies associees au recepteur orl-1
WO2005016913A1 (fr) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US7354925B2 (en) * 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (fr) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose
BRPI0910607A2 (pt) * 2008-03-27 2015-09-22 Gruenenthal Gmbh derivados do ciclohexano espirocíclicos substituídos

Also Published As

Publication number Publication date
ME01537B (me) 2014-04-20
DOP2012000135A (es) 2012-08-15
AU2010319581B2 (en) 2013-12-19
PT2501703E (pt) 2013-11-26
HN2012001011A (es) 2015-08-31
KR101363830B1 (ko) 2014-02-14
AU2010319581A1 (en) 2012-06-07
CO6541545A2 (es) 2012-10-16
EA020848B1 (ru) 2015-02-27
WO2011060035A1 (fr) 2011-05-19
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
CA2796161C (fr) 2015-03-17
TW201127841A (en) 2011-08-16
JP5680101B2 (ja) 2015-03-04
KR20130026523A (ko) 2013-03-13
MX2012005691A (es) 2012-06-13
UA107943C2 (en) 2015-03-10
JO2887B1 (en) 2015-03-15
CR20130087A (es) 2013-04-17
ECSP12011902A (es) 2012-07-31
US20110118251A1 (en) 2011-05-19
AU2010319581C1 (en) 2014-05-15
JP2013510859A (ja) 2013-03-28
PL2501703T3 (pl) 2014-02-28
IL219370A0 (en) 2012-06-28
EP2501703A1 (fr) 2012-09-26
CN102612520B (zh) 2015-04-08
EA201290352A1 (ru) 2012-10-30
ES2435814T3 (es) 2013-12-23
PE20121430A1 (es) 2012-10-26
CA2796161A1 (fr) 2011-05-19
SI2501703T1 (sl) 2013-11-29
NZ600006A (en) 2014-05-30
IL219370A (en) 2015-01-29
HRP20130967T1 (hr) 2013-11-22
HK1169988A1 (en) 2013-02-15
US8232289B2 (en) 2012-07-31
DK2501703T3 (da) 2013-10-14
MY160665A (en) 2017-03-15
CN102612520A (zh) 2012-07-25
EP2501703B1 (fr) 2013-09-18
AR078863A1 (es) 2011-12-07
RS53018B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
MA33751B1 (fr) Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1
PT2501704E (pt) Compostos de espiropiperidina como antagonistas do receptor orl-1
EP1793827A4 (fr) Antagonistes des recepteurs cgrp sous forme de spirolactame d'anilide tricyclique
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE537153T1 (de) Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
WO2006029153A3 (fr) Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
WO2008112159A3 (fr) Antagonistes des récepteurs cgrp d'anilide spirolactame monocyclique
PH12014502280A1 (en) Indole and indazole compounds that activate ampk
EP1606286A4 (fr) Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
ATE518852T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
EP1605936A4 (fr) Antagonistes du recepteur cgrp d'aryl spirohydantoine
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MY148544A (en) Pyridyl piperidine orexin receptor antagonists
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
TW200505903A (en) CGRP receptor antagonists
MA31766B1 (fr) Composés organiques
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
MX2013005246A (es) Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano.
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA34377B1 (fr) Composé de pipéridinyle en tant que modulateur de l'activité des récepteurs des chimiokines
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren